The study suggests sedating patients may reduce the risk of post-operative delirium by up to 65 per cent.
The condition may affect up to one in three people who have a major operation, causing confusion and hallucinations - with the over-65s particularly at risk.
The team, including scientists at Peking University First Hospital in China, believes the sedative may help the brain 'recover and reset' after surgery.
Post-operative delirium usually strikes within the first two days of a person waking from general anaesthetic.
"Post-operative delirium is a huge challenge for the medical community - and incredibly distressing for patients and their families," said Professor Daqing Ma, from the Imperial College London in the UK.
"In many cases patients become almost child-like, and do not understand where they are, what is happening, and become very upset. Hospital staff have also been injured by delirious patients becoming aggressive," said Ma.
The causes are unknown, but one theory is that major surgery can trigger inflammation throughout the body, which in some cases can spread to the brain.
The delirium can last from a few hours to a couple of days, and some research suggests it may be linked to an increased risk of elderly patients later developing dementia.
In the new study, researchers assessed 700 patients age 65 or older who were about to undergo major surgery.
Half received a low dose of a type of sedative called dexmedetomidine after the operation, as an infusion directly into a vein in their arm, while half received a placebo salt-water infusion.
This sedative, which is commonly used for medical procedures and in veterinary medicine, leaves a patient relaxed and drowsy, yet conscious. The drug is considered safe as it does not affect breathing.
Both groups received the same general anaesthetic before undergoing their operation. They were then assessed for symptoms of delirium every day for a week after procedure.
The results showed that nearly one in four patients in the placebo group - 23 per cent - developed delirium. However only just under one in ten patients - 9 per cent - who received the sedative developed the condition.
The study was published in The Lancet journal.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
